[go: up one dir, main page]

AR041024A1 - Derivados de benzimidazol como inhibidores del factor de coagulacion xa - Google Patents

Derivados de benzimidazol como inhibidores del factor de coagulacion xa

Info

Publication number
AR041024A1
AR041024A1 ARP030103008A ARP030103008A AR041024A1 AR 041024 A1 AR041024 A1 AR 041024A1 AR P030103008 A ARP030103008 A AR P030103008A AR P030103008 A ARP030103008 A AR P030103008A AR 041024 A1 AR041024 A1 AR 041024A1
Authority
AR
Argentina
Prior art keywords
hal
coor2
con
atoms
het
Prior art date
Application number
ARP030103008A
Other languages
English (en)
Inventor
Cezanne Bertram Dr
Mederski Werner Dr
Tsaklakidis Christos Dr
Gleitz Johannes Dr
Dorsh Dieter Dr
Barnes Christopher Dr
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of AR041024A1 publication Critical patent/AR041024A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Los nuevos compuestos de la fórmula (1) en la cual D es un anillo carbocíclico o heterocíclico aromático que tiene de 0 a 4 átomos de N, O y/o S, que está insustituido o monosustituido o polisustituido por Hal, A, OR2, N(R2), NO2, CN, COOR2 o CON(R2)2, X y X' son cada uno, en forma independiente entre sí, H, Hal, A, OR2, N(R2)2, NO2, CN, COOR2 o CON(R2)2, R1 es H o A, R2 es H, A, -[C(R1)2]n-Ar', -[C(R1)2]n-Het', -[C(R1)2]n-cicloalquilo, -[C(R1)2n-N(R1)2 o -[C(R1)2]n-OR1, W es _[C(R2)2]nCONR2[C(R2)2]n-, [C(R")2]nNR2CO[C(R2)2]-, [C(R2)2]nO[C(R2)2]-, -[C(R2)2]NNR2[C(R2)2]n-, -[C(R2)2]O[C(R2)2]nCONR2[C(R2)2]n-, -[C(R2)2]nNR2[C(R2)2]n-, -[C(R2)2]nNR2COO[C(R2)2]n- o -[C(R2)2]nS(O)m[C(R2)2]nCONR2[C(R2)2]n-, Y es alqiuleno, cicloalquileno, Het-diilo o Ar-diilo, es un anillo carbocíclico o heterocíclico monocíclico o bicíclico, saturado, no saturado o aromático que tiene de 0 a 4 átomos de N, O y/o S que está insustituido o monosustituido, disustituido o trisustituido por =O, =S, =NR2, =N-CN, =N-NO2, =NOR2, NCOR2, =NCOOR2, NOCOR2, R2,Hal, -[C(R1)2]n- Ar, -[C(R1)2]n-Het, [C(R1)2]n - cicloalquilo, OR2, N(R2)2, NO2, CN, COOR2, CON(R2)2, NR2COA, NR2SO2A, COR y/o S(O)mA, A es alquilo no ramificado o ramificado que tiene 1-10 átomos de carbono, en uno o dos grupos CH2 pueden estar reemplazados por átomos de O o S y/o por grupos -CH=CH- y/o además 1-7 átomos de H pueden estar reemplazados por F, Ar es fenilo, naftilo o bifenilo, cada uno de los cuales está insustituido o monosustituido, disustituido o trisustituido por Hal, A, OR2, N(R2)2, NO2, CN, COOR2, CON(R2)2, NR2COA, NR2CON(R2)2, NR2SO2A, COR2, SO2N(R2)2, S(O)mA, -[(R1)2]n-COOR2 u -O-[C(R1)2]o -COOR2, Ar' es fenilo que está insustituido o monosustituido, disustituido o trisustituido por Hal, A, OR1, N(R1)2, NO2, CN, COOR1, CON(R1)2, NR1COA, NR1SO2A, COR1, SO2N(R1)2, S(O)mA, -[C(R1)2]n, COOR1 u -O-[C(R1)2]o-COOR1, Het es un anillo heterocíclico monocíclico o bicíclico, saturado, no saturado o aromático que tiene de 1 a 4 átomos de N, O y/o S que está insustituido o monosustituido, disustituido o trisustituido por el oxígeno del carbonilo, =S, =N(R1)2, Hal, A, -[C(R1)2]n-Ar, -[C(R1)2]n-Het', -[C(R1)2]n-cicloalquilo, -[C(R1)2]n-OR2, -[C(R1)2]n-N(R2)2, NO2, CN, -[C(R1)2]n-.COOR2, -[C(R1)2]n-CON(R2)2, -[C(R1)2]nNR2COA, NR2CON(R2)23, -[C(R1)2]n-NR2SO2A, COR2, SO2N(R2)2 y/o S(O)mA, Het' es un anillo heterocíclico monocíclico o bicíclico, saturado, no saturado o aromático que tiene de 1 a 4 átomos de N, O y/o S que está insustituido o monosustituido o disustituido por el oxígeno del carbonilo, =S, =N(R1)2, Hal, A, OR1, N(R1)2, NO2, CN, COOR1, CON(R1)2, NR1SO2A, COR1, SO2N(R1)2 y/o S(O)mA, Hal es F, Cl, Br o I, m es 0, 1 ó 2, n es 0, 1 ó 2, o es 1, 2 o 3, y derivados, solvatos y estereoisómeros de ellos de uso farmacéutico, incluyendo sus mezclas en todas las proporciones. Son inhibidores del factor de coagulación Xa y pueden emplearse para la profilaxis y/o la terapia de enfermedades tromboembólicas y para el tratamiento de tumores.
ARP030103008A 2002-08-20 2003-08-20 Derivados de benzimidazol como inhibidores del factor de coagulacion xa AR041024A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10238002A DE10238002A1 (de) 2002-08-20 2002-08-20 Benzimidazolderivate

Publications (1)

Publication Number Publication Date
AR041024A1 true AR041024A1 (es) 2005-04-27

Family

ID=31197107

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030103008A AR041024A1 (es) 2002-08-20 2003-08-20 Derivados de benzimidazol como inhibidores del factor de coagulacion xa

Country Status (13)

Country Link
US (1) US7566789B2 (es)
EP (1) EP1558247B1 (es)
JP (1) JP4668614B2 (es)
CN (1) CN1674893A (es)
AR (1) AR041024A1 (es)
AT (1) ATE386518T1 (es)
AU (1) AU2003250890B2 (es)
BR (1) BR0313634A (es)
CA (1) CA2496139C (es)
DE (2) DE10238002A1 (es)
ES (1) ES2303606T3 (es)
RU (1) RU2005108042A (es)
WO (1) WO2004017963A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2275102B1 (en) 2002-03-13 2015-07-29 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
AU2003279735A1 (en) * 2002-10-02 2004-04-23 Bristol-Myers Squibb Company Lactam-containing diaminoalkyl, beta-aminoacids, alpha-aminoacids and derivatives thereof as factor xa inhibitors
KR20060105872A (ko) * 2003-12-29 2006-10-11 반유 세이야꾸 가부시끼가이샤 신규한 2-헤테로아릴 치환된 벤즈이미다졸 유도체
CA2562763A1 (en) 2004-04-23 2006-07-20 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
TW200720255A (en) 2005-07-13 2007-06-01 Taiho Pharmaceutical Co Ltd Benzoimidazole compound capable of inhibiting prostaglandin d synthetase
US7799820B2 (en) 2005-09-30 2010-09-21 Banyu Pharmaceutical Co., Ltd. 2-Heterocycle-substituted indole derivatives for treating diabetes and associated conditions
EP2102189B1 (en) 2006-12-15 2015-07-29 Bristol-Myers Squibb Company Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
WO2009075874A1 (en) * 2007-12-13 2009-06-18 Amgen Inc. Gamma secretase modulators
AU2009244504A1 (en) * 2008-05-05 2009-11-12 Amgen Inc. Urea compounds as gamma secretase modulators
PA8854101A1 (es) 2008-12-18 2010-07-27 Ortho Mcneil Janssen Pharm Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa
EP2393804B1 (en) 2009-02-06 2014-04-16 Janssen Pharmaceuticals, Inc. Novel substituted bicyclic heterocyclic compounds as gamma secretase modulators
TWI461425B (zh) 2009-02-19 2014-11-21 Janssen Pharmaceuticals Inc 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類
NZ596843A (en) 2009-05-07 2012-12-21 Janssen Pharmaceuticals Inc Novel substituted indazole and aza-indazole derivatives as gamma secretase modulators
AU2010272578B2 (en) 2009-07-15 2015-03-05 Cellzome Limited Substituted triazole and imidazole derivatives as gamma secretase modulators
RU2570426C2 (ru) * 2009-12-18 2015-12-10 Мицубиси Танабе Фарма Корпорейшн Новое антитромботическое средство
WO2011086099A1 (en) 2010-01-15 2011-07-21 Ortho-Mcneil-Janssen Pharmaceuticals, Inc Novel substituted triazole derivatives as gamma secretase modulators
MX2013010970A (es) 2011-03-24 2013-10-17 Cellzome Ltd Novedosos derivados de triazolil piperazina y triazolil piperidina sustituidos como moduladores de gamma-secretasa.
CA2841102C (en) 2011-07-15 2019-08-13 Janssen Pharmaceuticals, Inc. Novel substituted indole derivatives as gamma secretase modulators
US20140315881A1 (en) * 2011-07-29 2014-10-23 Tempero Pharmaceuticals, Inc. Compounds and methods
EA027242B1 (ru) 2012-05-16 2017-07-31 Янссен Фармасьютикалз, Инк. ЗАМЕЩЕННЫЕ 3,4-ДИГИДРО-2H-ПИРИДО[1,2-a]ПИРАЗИН-1,6-ДИОНОВЫЕ ПРОИЗВОДНЫЕ, ПРИМЕНИМЫЕ ДЛЯ ЛЕЧЕНИЯ (В ТОМ ЧИСЛЕ) БОЛЕЗНИ АЛЬЦГЕЙМЕРА
CA2889249C (en) 2012-12-20 2021-02-16 Francois Paul Bischoff Tricyclic 3,4-dihydro-2h-pyrido[1,2-a]pyrazine-1,6-dione derivatives as gamma secretase modulators
JP6283691B2 (ja) 2013-01-17 2018-02-21 ヤンセン ファーマシューティカ エヌ．ベー． γセクレターゼ調節剤としての新規な置換ピリド−ピペラジノン誘導体
CN103396405A (zh) * 2013-08-21 2013-11-20 中国药科大学 具有parp抑制作用的苯并咪唑-4-甲酰胺衍生物
US10562897B2 (en) 2014-01-16 2020-02-18 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
US10011585B2 (en) 2014-07-28 2018-07-03 Merck Sharp & Dohme Corp. Factor XIa inhibitors
HUE059537T2 (hu) * 2014-10-08 2022-11-28 Redx Pharma Plc N-piridinil-acetamid-származékok, mint WNT jelátviteli útvonal inhibitorok
CN105712937B (zh) * 2016-02-28 2019-02-22 河北宁格生物医药科技有限公司 一种治疗转移性肿瘤的化合物及其用途
MX2024000313A (es) 2021-07-09 2024-03-06 Plexium Inc Compuestos de arilo y composiciones farmaceuticas que modulan la ikzf2.

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2641060A1 (de) * 1976-09-11 1978-03-16 Hoechst Ag Beta-lactamverbindungen und verfahren zu ihrer herstellung
JP2869561B2 (ja) * 1989-05-22 1999-03-10 大塚製薬株式会社 血小板粘着抑制剤
JPH06759B2 (ja) * 1989-09-22 1994-01-05 ファイザー製薬株式会社 新規なベンゾイミダゾール化合物
GB9225141D0 (en) * 1992-12-01 1993-01-20 Smithkline Beecham Corp Chemical compounds
DE4330959A1 (de) 1993-09-09 1995-03-16 Schering Ag Neue Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
IL113472A0 (en) * 1994-04-29 1995-07-31 Lilly Co Eli Non-peptidyl tachykinin receptor antogonists
US5849759A (en) * 1995-12-08 1998-12-15 Berlex Laboratories, Inc. Naphthyl-substituted benzimidazole derivatives as anti-coagulants
US6150379A (en) * 1997-11-26 2000-11-21 Axys Pharmaceuticals, Inc. Compounds and compositions as anticoagulants
US6344450B1 (en) * 1999-02-09 2002-02-05 Bristol-Myers Squibb Company Lactam compounds and their use as inhibitors of serine proteases and method
AU5723500A (en) 1999-05-24 2000-12-12 Cor Therapeutics, Inc. Inhibitors of factor xa
EE04813B1 (et) * 1999-06-23 2007-04-16 Aventis Pharma Deutschland Gmbh Asendatud bensimidasoolid, nende saamine ning kasutamine ravimi valmistamiseks, mis on ette nähtud NFkB aktiivsuse suurenemisest tingitud haiguste profülaktikaks ja raviks
WO2001028993A2 (en) * 1999-10-19 2001-04-26 Merck & Co. Inc. Tyrosine kinase inhibitors
DE60115069T2 (de) * 2000-09-11 2006-08-03 Chiron Corp., Emeryville Chinolinonderivate als tyrosin-kinase inhibitoren
EP1401831A1 (en) * 2001-07-03 2004-03-31 Chiron Corporation Indazole benzimidazole compounds as tyrosine and serine/threonine kinase inhibitors
DE10139060A1 (de) * 2001-08-08 2003-02-20 Merck Patent Gmbh Phenylderivate

Also Published As

Publication number Publication date
AU2003250890B2 (en) 2009-07-16
DE10238002A1 (de) 2004-03-04
EP1558247A1 (de) 2005-08-03
WO2004017963A1 (de) 2004-03-04
BR0313634A (pt) 2005-06-21
ATE386518T1 (de) 2008-03-15
CA2496139C (en) 2011-12-13
CN1674893A (zh) 2005-09-28
RU2005108042A (ru) 2005-11-20
CA2496139A1 (en) 2004-03-04
DE50309217D1 (en) 2008-04-03
JP4668614B2 (ja) 2011-04-13
JP2006500369A (ja) 2006-01-05
US20050272740A1 (en) 2005-12-08
ES2303606T3 (es) 2008-08-16
AU2003250890A1 (en) 2004-03-11
EP1558247B1 (de) 2008-02-20
US7566789B2 (en) 2009-07-28

Similar Documents

Publication Publication Date Title
AR041024A1 (es) Derivados de benzimidazol como inhibidores del factor de coagulacion xa
AR043832A1 (es) Compuestos de carbonilo y proceso de preparacion de los mismos
SV2008002958A (es) Uso de derivados de sulfamida heterociclo benzo-fusionado para el tratamiento del trastorno bipolar y mania referencia cruzada ref. prd2592sv
PE20020337A1 (es) DERIVADOS DE IMIDAZOL COMO INHIBIDORES DE QUINASA DEPENDIENTES DE CICLINA cdk5 Y cdk2
EA201591932A1 (ru) ПРИМЕНЕНИЕ ЗАМЕЩЕННЫХ 2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИНОВ ДЛЯ ЛЕЧЕНИЯ ЛИМФОМ
AR038202A1 (es) Compuestos de indazol utiles como inhibidores de la proteina quinasa
AR050945A1 (es) Medicamentos que contienen compuestos de carbonilo y su uso
ECSP045407A (es) Benzazoles sustituidos y el uso del mismo como inhibidores de quinasa raf
UY27095A1 (es) Derivados benzimidazol y piridilimidazol como ligandos para gaba
AR069244A1 (es) Metodos para administrar n-( 5- ter- butil- isoxixasol-3-il) -n'- (4(7-(2- morfolin-4-il- etoxi) imidazo (2,1-b) (1,3) benzotiazol -2-il) fenil) urea para tratar una enfermedad proliferante y composicion farmaceutica
BRPI0014722B8 (pt) compostos inibidores de sglt2, composição farmacêutica e uso dos referidos compostos
AR024242A1 (es) COMPUESTO HETEROBICICLO CON CONTENIDO DE NITROGENO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE , Y EL USO DE DICHOS COMPUESTOS EN LA FABRICACIoN DE UN MEDICAMENTO.
AR029805A1 (es) Compuestos heterociclicos, un proceso para su preparacion , intermediarios, composicion farmaceutica, un proceso para su preparacion, y el uso de dichos compuestos para la fabricacion de un medicamento
ECSP055609A (es) "Uso de inhibidores de la IkB-quinasa para el tratamiento del dolor"
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
CO6220964A2 (es) Derivados de piridazinona
CR10167A (es) "uso de derivados de sulfamida heterociclica benzo-fusionada para el tratamiento de dolor"
MX9303469A (es) Derivados de benzimidazol, procedimiento para su preparacion, composicion farmaceutica que los contiene y procedimiento para preparar de la misma.
AR045626A1 (es) Derivados del bencil- bencimidazolilo
AR081828A1 (es) Compuestos de biguanida y su uso para el tratamiento del cancer
CL2022002148A1 (es) Inhibidores heterocíclicos de pad4
AR007021A1 (es) Derivados de 3-descladinosa-2,3-anhidroeritromicina, procedimientos para su preparacion, compuestos para su exclusivo uso en dichos procedimientosy procedimiento para su preparacion, una composicion farmaceutica para tratar infecciones bacterianas y el uso de estos compuestos para preparar medicamentos
UY27452A1 (es) Compuestos de benzimidazol sustituido y su uso para el tratamiento del cancer
MX2024008057A (es) Compuestos de pirazina como inhibidores de flt3.
CL2022003039A1 (es) Inhibidores de il4i1 y métodos de uso.

Legal Events

Date Code Title Description
FB Suspension of granting procedure